Assessment of Kratom Use Disorder and Withdrawal Among an Online Convenience Sample of US Adults

被引:23
作者
Smith, Kirsten E. [1 ]
Dunn, Kelly E. [2 ]
Rogers, Jeffrey M. [1 ]
Garcia-Romeu, Albert [2 ]
Strickland, Justin C. [2 ]
Epstein, David H. [1 ]
机构
[1] NIDA, Real World Assessment Predict & Treatment Unit, Intramural Res Program, Baltimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA
关键词
assessment; kratom; kratom use disorder; Mitragyna speciosa; opioids;
D O I
10.1097/ADM.0000000000000986
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Introduction: Since 2007, kratom use in the United States has increased, centered around nonmedical self-treatment of pain, psychiatric, and substance use disorder symptoms. Reports of kratom withdrawal have emerged amidst description of therapeutic effects, yet we know little about disordered use. Our objective was to assess Diagnostic and Statistical Manual-5 substance use disorder for kratom ("kratom use disorder," KUD) and examine kratom withdrawal symptoms among those who ever used regularly. We also sought to identify clinical characteristics of respondents who qualified for current, remitted, or never KUD. Methods: Between April and May 2021, we re-recruited online respondents who reported lifetime kratom use on an unrelated survey into our cross-sectional kratom survey study, permitting a diverse sample of current and former kratom-using persons. Results: A total of 129/289 (44.6%) evaluable surveys were obtained. Over half (52.7%) of respondents never met KUD diagnostic criteria; 17.8% were assessed remitted, and 29.5% met current (past-year) KUD threshold. For past-year KUD, severity was: 14.0% mild, 7.0% moderate, and 8.5% severe. Pain, psychiatric symptoms, and polydrug use were found across all groups. KUD symptoms reflected increased use, tolerance, withdrawal, unsuccessful quit attempts, and craving; 9.3% reported decreases in important social, occupational, or recreational activities because of use. Withdrawal symptoms were moderate and included gastrointestinal upset, restlessness, anxiety, irritability, fatigue/low energy, and craving. Conclusions: As assessed here, tolerance and withdrawal are primary KUD features rather than psychosocial impairments. As kratomis often used among persons with a myriad of health conditions, clinicians should be aware of and assess for kratom use and withdrawal.
引用
收藏
页码:666 / 670
页数:5
相关论文
共 15 条
[1]   Outpatient buprenorphine induction and maintenance treatment for kratom dependence: A case study [J].
Agapoff, James R. ;
Kilaru, Usha .
JOURNAL OF SUBSTANCE USE, 2019, 24 (06) :575-577
[2]   Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method [J].
Berthold, Erin C. ;
Kamble, Shyam H. ;
Raju, Kanumuri S. ;
King, Tamara, I ;
Popa, Raluca ;
Sharma, Abhisheak ;
Leon, Francisco ;
Avery, Bonnie A. ;
McMahon, Lance R. ;
McCurdy, Christopher R. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 194
[3]   A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management [J].
Bowe, Adina ;
Kerr, Patrick L. .
JOURNAL OF PSYCHOACTIVE DRUGS, 2020, 52 (05) :447-452
[4]   Exploring the Chemistry of Alkaloids from Malaysian Mitragyna speciosa (Kratom) and the Role of Oxindoles on Human Opioid Receptors [J].
Chear, Nelson Jeng-Yeou ;
Leon, Francisco ;
Sharma, Abhisheak ;
Kanumuri, Siva Rama Raju ;
Zwolinski, Grant ;
Abboud, Khalil A. ;
Singh, Darshan ;
Restrepo, Luis F. ;
Patel, Avi ;
Hiranita, Takato ;
Ramanathan, Surash ;
Hampson, Aidan J. ;
McMahon, Lance R. ;
McCurdy, Christopher R. .
JOURNAL OF NATURAL PRODUCTS, 2021, 84 (04) :1034-1043
[5]   u Kratom as a substitute for opioids: Results from an online survey [J].
Coe, Marion A. ;
Pillitteri, Janine L. ;
Sembower, Mark A. ;
Gerlach, Karen K. ;
Henningfield, Jack E. .
DRUG AND ALCOHOL DEPENDENCE, 2019, 202 :24-32
[6]   A comparative analysis of kratom exposure cases in Thailand and the United States from 2010-2017 [J].
Davidson, Christian ;
Cao, Dazhe ;
King, Taylore ;
Weiss, Stephanie T. ;
Wongvisavakorn, Sunun ;
Ratprasert, Natthasiri ;
Trakulsrichai, Satariya ;
Srisuma, Sahaphume .
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2021, 47 (01) :74-83
[7]   Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic [J].
Garcia-Romeu, Albert ;
Cox, David J. ;
Smith, Kirsten E. ;
Dunn, Kelly E. ;
Griffiths, Roland R. .
DRUG AND ALCOHOL DEPENDENCE, 2020, 208
[8]   Patterns of Kratom use and health impact in the US-Results from an online survey [J].
Grundmann, Oliver .
DRUG AND ALCOHOL DEPENDENCE, 2017, 176 :63-70
[9]   Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats [J].
Kamble, Shyam H. ;
Berthold, Erin C. ;
King, Tamara, I ;
Kanumuri, Siva Rama Raju ;
Popa, Raluca ;
Herting, Julius R. ;
Leon, Francisco ;
Sharma, Abhisheak ;
McMahon, Lance R. ;
Avery, Bonnie A. ;
McCurdy, Christopher R. .
JOURNAL OF NATURAL PRODUCTS, 2021, 84 (04) :1104-1112
[10]   Treatment of Kratom Withdrawal and Addiction With Buprenorphine [J].
Khazaeli, Azin ;
Jerry, Jason M. ;
Vazirian, Mohsen .
JOURNAL OF ADDICTION MEDICINE, 2018, 12 (06) :493-495